1. Introduction {#s0005}
===============

[l]{.smallcaps}-arginine is a precursor in the synthesis of numerous biologically important molecules whose signaling is limited to a great extent by their availability, as well as by the expression and activity of multiple enzymes involved in their metabolism ([@b0280], [@b0100]). One of the most important biomolecules originating from [l]{.smallcaps}-arginine is NO which functions as a cell signaling molecule in mammalian cells, controlling vital functions such as neurotransmission, blood vessel tone, host defense and immunity ([@b0165]). The enzyme that catalyzes NO production from the guanidine group of [l]{.smallcaps}-arginine in an NADPH-dependent reaction is nitric oxide synthase (NOS), which is present in at least three distinct isoforms: neuronal NOS (nNOS, or NOS1), inducible NOS (iNOS, or NOS2), and endothelial NOS (eNOS, or NOS3). The recognition that all three isoforms of NOS are expressed in cardiomyocytes has raised several intriguing questions regarding the signaling role of NO in the heart. NO is produced from virtually all cell types composing the myocardium and regulates cardiac function through both vascular-dependent and -independent effects. NO acts as a negative inotrope in cardiac muscle ([@b0020]), and exerts a hypotensive effect *via* peripheral artery dilatation, thus decreasing afterload, and it reduces the preload by the dilatation of the venous system ([@b0265]). Besides its hemodynamic actions, however, the direct anti-proliferative effects of NO may play an important role ([@b0105], [@b0235]), since NO seems to be an important factor in modulating hypertrophic heart growth ([@b0135], [@b0265], [@b0195], [@b0260]).

Cardiac hypertrophy refers to the process of cardiac thickening and remodeling and may be due to cardiac pathology, long-term exercise training ([@b0190], [@b0130]) or chronic cold exposure ([@b0030]). In pathological cardiac hypertrophy, myocardial structure is affected by two key pathological processes: cardiomyocyte hypertrophy and a progressive accumulation of connective tissue within the myocardial interstitium-myocardial fibrosis ([@b0065], [@b0230], [@b0070]). The main etiological factor of pathological cardiac hypertrophy is hypertension-induced chronic pressure overload ([@b0200]). In contrast, during conditions of increased hemodynamic requirements, such are during sustained exercise training or during prolonged cold exposure, so-called physiologic cardiac hypertrophy occurs (a condition known as "athlete heart" as a result of cardiac adaptation to long-term training). Physiologic cardiac hypertrophy is characterized by preserved myocardial structure, with a normal pattern of gene expression and collagen metabolism, and does not progress to ventricular dysfunction ([@b0220]).

Since NO is the endothelium-derived relaxing factor essential for regulating vascular tone and hemodynamics ([@b0095]), there has been a growing interest in [l]{.smallcaps}-arginine supplementation to prevent and treat cardiovascular disorders. Endothelial dysfunction due to impaired NO bioavailability in the vasculature plays an important role in the development of cardiovascular disease. Patients with chronic heart failure display signs of disturbed endothelial function in coronary arteries ([@b0225]) and in the peripheral circulation ([@b0115]). Since [l]{.smallcaps}-arginine availability is a rate-limiting step for NOS ([@b0010], [@b0160], [@b0250]) and its decreased availability results in a decreased NO production ([@b0285]), this amino acid is widely available and publicized as having benefits in the prevention and treatment of cardiovascular disorders ([@b0145], [@b0015]) and atherosclerosis risk factors, all of which are conditions that are associated with reduced NO biosynthesis ([@b0050], [@b0040], [@b0215], [@b0005], [@b0125]). Dietary supplements containing [l]{.smallcaps}-arginine are also claimed to have effects in healthy subjects by promoting vasodilatation which improves perfusion and delivery of nutrients and oxygen to various organs. However, less is known about how [l]{.smallcaps}-arginine supplementation affects the structure and function of pathologically unaltered hearts.

In contrast, chronic inhibition of NOS by N^ω^-nitro-[l]{.smallcaps}-arginine methyl ester ([l]{.smallcaps}-NAME) is a well-established model of experimental hypertension and cardiac hypertrophy ([@b0180]). The vascular effects of [l]{.smallcaps}-NAME have been demonstrated to involve the removal of the tonic vasodilator action of NO by eNOS inhibition ([@b0075], [@b0045], [@b0270]) and stimulation of the sympathetic nervous system *via* nNOS inhibition ([@b0035]).

One of the important factors in increasing heart workload is cold exposure. The ability of homeotherms to make the necessary physiological and metabolic adaptations when subjected to cold is important for their survival. These include increased heat production that is fueled by increased food intake and/or mobilization of body reserves which often results in a decreased body weight gain, nitrogen balance, and skeletal muscle accretion ([@b0245], [@b0150]). There is also an attendant increase in the size of the heart ([@b0090], [@b0080], [@b0245]) and its protein mass ([@b0150]), which likely reflects its higher workload in support of the increased thermogenesis. As we have already demonstrated [l]{.smallcaps}-arginine-induced enhancement of thermogenic activity in brown adipose tissue ([@b0210]) and [l]{.smallcaps}-arginine-induced intensification of antioxidative defense processes in the skeletal muscle of cold-acclimated rats ([@b0205]), it is expected that [l]{.smallcaps}-arginine will further affect myocardial load in rats acclimated to cold.

The aim of this study was to determine whether chronic oral administration of [l]{.smallcaps}-arginine and [l]{.smallcaps}-NAME to adult male rats (maintained at room temperature or acclimated to cold) affected myocardial structure. Structural changes were characterized by microscopic, stereological and morphometric examinations.

2. Materials and methods {#s0010}
========================

2.1. Experimental design {#s0015}
------------------------

The experiment was approved by the Ethical Committee for the Treatment of Experimental Animals of the Institute of Biological Research "Sinisa Stankovic", University of Belgrade, and the animals were cared for in accordance with the principles of the *Guide to the Care and Use of Experimental Animals*. Male Mill Hill hybrid-hooded, 2-month-old rats were used. They were divided into three main groups. The first group received [l]{.smallcaps}-arginine·HCl (2.25%), and the second group received [l]{.smallcaps}-NAME·HCl, (0.01%), in drinking water for 45 days. The third, untreated group served as a control, and received tap water. The animals in all three groups were further divided into two groups -- one group was kept in a cold room at 4 ± 1 °C and the other group was kept at room temperature (22 ± 1 °C). Each group consisted of six animals. The animals were kept in individual cages, with food and drinking liquids *ad libitum*. At the end of the experimental period the animals were sacrificed; hearts were isolated immediately and prepared for microscopic analyses.

2.2. Microscopic analyses {#s0020}
-------------------------

In order to obtain isotropic and uniform random sections for stereological and morphometric studies of right ventricle, the unbiased design-based approach to the quantitative study of anisotropic structures -- the orientator method ([@b0140]) was performed. The right ventricles were cut at random; then placed on cut surface and again cut at random, perpendicular to the first plane. The specimens were again placed on the new cut surface and a new random orientation is defined by cutting the organ in a perpendicular section to the plane. The last cut is considered uniformly isotropic, meaning that without reference to the position of the specimen in the first cut the last surface has an orientation that varies from all possible ones. One half of the randomly selected heart right ventricle samples from each animal was fixed in 2.5% glutaraldehyde, postfixed in 1% osmium tetroxide and embedded in Araldite (Fluka, Germany). Semi-fine serial sections were cut using an ultramicrotome (Leica, Germany) and stained with toluidine blue. Micrographs (magnification 100 × 10) of each section were obtained for stereological and morphometric analyses (Axio Imager M1, Carl Zeiss, Germany). The other half of the randomly selected heart right ventricle samples was fixed in buffered 10% formalin and embedded in paraffin. Five-μm thick paraffin sections were cut using a microtome (Reichert, Austria), stained with Azan trichrome and analyzed microscopically (Axio Imager M1). Micrographs (magnification 100 × 10) were obtained for histological analysis and morphometric analysis of cardiomyocyte diameters.

2.3. Morphometric and stereological analyses {#s0025}
--------------------------------------------

### 2.3.1. Estimations of volume densities of cardiomyocytes, blood vessels and connective tissue in the myocardium {#s0030}

The volume densities of the major myocardial components (cardiomyocytes, blood vessels and connective tissue) were obtained using a standard point-counting technique ([@b0275]) and the ImageJ image analysis system (NIH, USA). This technique allows the determination of the volume fraction of each compartment as a ratio of the number of points falling on the compartment relative to the total number of points falling on the myocardial tissue. An orthogonal grid with 8 × 10 intersections was superimposed on light micrographs at a final magnification of ×1000 (15 micrographs per animal). Volume densities were expressed as percentage fractions of cardiac muscle tissue.

### 2.3.2. Measurement of cardiomyocyte diameters {#s0035}

Morphometric evaluation of cardiomyocyte diameters was performed using the ImageJ image analysis system. Measurements were performed exclusively on longitudinal azan trichrome-stained sections of myocardium. 150--260 cardiomyocyte diameters per animal were analyzed in the central region of the cell (nuclear level). Results are presented as mean value ±SEM. In order to follow the trend in cardiomyocyte diameter change, a histogram of cardiomyocyte size distribution was constructed with a class interval of 5 μm.

### 2.3.3. Statistical analysis {#s0040}

To test data for normality, the Kolmogorov--Smirnov test was used. Analysis of variance (ANOVA) was used for within-group comparisons of the data. If the *F* test showed an overall difference, Student's *t*-test was used to evaluate the significance of the differences in cases of parametric distribution, or Mann--Whitney test in cases of non-parametric distribution. Statistical significance was set at *p* \< 0.05.

3. Results {#s0045}
==========

3.1. Volume densities of cardiomyocytes, blood vessels and connective tissue in the myocardium {#s0050}
----------------------------------------------------------------------------------------------

The results of stereological analyses of volume densities of cardiomyocytes, blood vessels and connective tissue are shown in [Table 1](#t0005){ref-type="table"}. Compared with the control group acclimated to room temperature, cold acclimation did not significantly change volume density of myocardial tissue components (cardiomyocytes, blood vessels, connective tissue), although a slight decrease in blood vessel volume density was observed.Table 1Volume densities of cardiomyocytes (Vv~cm~), blood vessels (Vv~bv~) and connective tissue (Vv~ct~) in the right ventricle myocardium of experimental groups. Compared with [l]{.smallcaps}-arginine treatment in room temperature-acclimated animals, [l]{.smallcaps}-arginine treatment in cold-acclimated animals increases cardiomyocyte volume density and decreases blood vessel volume density. [l]{.smallcaps}-NAME treatment increases connective tissue volume density and decreases cardiomyocyte volume density. Values are presented as mean ± SEM. Statistically significant differences *vs.* referent control: (\*) *p* \< 0.05, (\*\*) *p* \< 0.01, (\*\*\*) *p* \< 0.001; statistically significant differences *vs.* identical treatment at room temperature: (\#\#) *p* \< 0.01, (\#\#\#) *p* \< 0.001.Room temperatureColdControl[l]{.smallcaps}-arginine[l]{.smallcaps}-NAMEControl[l]{.smallcaps}-arginine[l]{.smallcaps}-NAMEVv~cm~ (%)82.25 ± 1.1679.49 ± 0.8677.82 ± 1.15 (\*\*)83.81 ± 1.2383.06 ± 1.58 (**\#\#**)78.88 ± 1.27 (**\*\***)Vv~bv~ (%)10.03 ± 0.7711.24 ± 0.7111.13 ± 0.678.97 ± 0.777.53 ± 0.62 (**\#\#\#**)7.94 ± 0.68 (**\#\#**)Vv~ct~ (%)7.73 ± 0.849.10 ± 0.5911.06 ± 1.15 (**\***)7.66 ± 0.799.82 ± 1.6912.49 ± 0.99 (**\*\*\***)

Chronic treatment with [l]{.smallcaps}-arginine at room temperature did not lead to statistically significant changes in volume densities of myocardial tissue components, although blood vessel and connective tissue volume densities have tended to increase. Chronic treatment with [l]{.smallcaps}-arginine in cold-acclimated animals also showed no significant changes in volume densities of tissue components, when compared with the appropriate control. However, when compared with [l]{.smallcaps}-arginine treatment at room temperature, cardiomyocyte volume density increased, while volume density of blood vessels decreased ([Table 1](#t0005){ref-type="table"}).

Both chronic treatments with [l]{.smallcaps}-NAME, irrespective of ambient temperature acclimation, led to increased connective tissue volume density associated with a decrease in cardiomyocyte volume density (when compared with appropriate controls). [l]{.smallcaps}-NAME treatment in cold-acclimated animals also decreased blood vessel volume density, when compared with the identical treatment in room-acclimated animals.

3.2. Structural alterations in myocardium {#s0055}
-----------------------------------------

The control and [l]{.smallcaps}-arginine-treated groups acclimated to room temperature and cold, respectively, showed correct arrangement of myofibrils inside cardiomyocytes with maintenance of myocardial striation ([Fig. 1](#f0005){ref-type="fig"}A, B, D and E). A small quantity of connective tissue with scarce collagen fibers was found around the cardiomyocytes.Figure 1Representative micrographs of longitudinal sections of the right ventricles myocardia from: control groups, [l]{.smallcaps}-arginine- and [l]{.smallcaps}-NAME-treated groups acclimated to room temperature (22 ± 1 °C) and cold (4 ± 1 °C), respectively. No signs of pathological alterations were observed in (A and D) control and (B and E) [l]{.smallcaps}-arginine-treated groups. In (C and F) both [l]{.smallcaps}-NAME-treated groups, distortion of correct myofibril arrangement in cardiomyocytes is visible. Also, collagen (blue) content in the interstitium is increased in these groups. Azan trichrome staining. Scale bars -- 50 μm.

In contrast, both the room temperature- and cold-acclimated [l]{.smallcaps}-NAME-treated groups ([Fig. 1](#f0005){ref-type="fig"}C and F) showed myofibril distortion inside the cardiomyocytes with consequent interruption of the correct myocardial striation pattern. Deposition of collagen fibers around the cardiomyocytes was also increased, leading to connective tissue growth in the myocardium of [l]{.smallcaps}-NAME-treated rats.

With regard to the capillary supply in the myocardium, a reduction was evident in all cold-acclimated groups ([Fig. 1](#f0005){ref-type="fig"}D--F).

3.3. Cardiomyocyte diameter {#s0060}
---------------------------

Compared with the control group acclimated to room temperature, increased cardiomyocyte diameter occurred in all experimental groups, however, the diameters were statistically different (*p* \< 0.01) only after [l]{.smallcaps}-arginine and [l]{.smallcaps}-NAME treatment in room temperature-acclimated animals ([Table 2](#t0010){ref-type="table"}).Table 2Hypertrophy of cardiomyocytes after chronic [l]{.smallcaps}-arginine and [l]{.smallcaps}-NAME treatment in both room temperature-acclimated and cold-acclimated animals. Cardiomyocyte diameters were measured in longitudinal sections at the nuclear level. Values are presented as mean ± SEM. (\*\*) *p* \< 0.01 -- statistically significant differences *vs.* referent control.Room temperatureColdControl[l]{.smallcaps}-arginine[l]{.smallcaps}-NAMEControl[l]{.smallcaps}-arginine[l]{.smallcaps}-NAMECardiomyocyte diameter (μm)16.08 ± 0.3317.25 ± 0.30 (**\*\***)17.29 ± 0.28 (**\*\***)16.98 ± 0.3717.44 ± 0.3717.27 ± 0.25

The distribution histogram of cardiomyocyte diameters confirmed these results, and showed a shift to greater diameters in all treated and cold-acclimated groups when compared to the room temperature-acclimated control group ([Fig. 2](#f0010){ref-type="fig"}).Figure 2Distribution of cardiomyocyte diameters according to their size. Compared with the room temperature-acclimated group, the percentage of cardiomyocytes with diameters over 15 μm increased in all treated and cold-acclimated groups.

4. Discussion {#s0065}
=============

In the present work, adult male rats were treated with [l]{.smallcaps}-arginine and [l]{.smallcaps}-NAME for 45 days, respectively, in order to examine the possible effects of NO on myocardial structure during room temperature- or cold-acclimation. Our results demonstrated that cold acclimation *per se* does not significantly alter the volume densities of myocardial tissue components, but leads to a trend in cardiomyocyte hypertrophy followed by a downward trend in capillarity.

[l]{.smallcaps}-Arginine treatment in room temperature-acclimated rats led to cardiomyocyte hypertrophy which was followed by a simultaneous increase in capillarity and interstitial connective tissue in the myocardium, maintaining the relative ratio of tissue components unaltered. Regardless of the increase in cardiomyocyte size, no statistically significant changes of their volume density or in blood vessels and connective tissue occurred in the myocardium. [l]{.smallcaps}-Arginine treatment following cold acclimation acts synergistically with cold by increasing cardiomyocyte size and decreasing myocardial capillarity. Compared to the room temperature-acclimated group treated with [l]{.smallcaps}-arginine, the volume density was additionally increased and was followed by a decrease in blood vessel volume density. This imbalance between cardiomyocyte enlargement and capillary supply could be considered to be the effect of cold, since a declining trend in myocardial capillarity was observed in all cold-acclimated groups.

Cardiomyocyte hypertrophy (enlargement) occurs *via* intracellular signaling pathways within these cells ([@b0085]) and is commonly connected with cardiac hypertrophy, which refers to cardiac thickening and remodeling. This process may be due to cardiac pathology, to long-term exercise training ([@b0190], [@b0130]) or chronic cold exposure ([@b0030]). Our results demonstrated that the structural alterations observed corresponded to physiologic cardiac hypertrophy since we were unable to identify any pathological changes in the myocardial structure (no signs of increased collagen deposition or myofibril distortion) after chronic [l]{.smallcaps}-arginine treatment in male rats. The observed hypertrophic effect of chronic [l]{.smallcaps}-arginine supplementation on cardiomyocytes is inconsistent with previous findings demonstrating the anti-proliferative effects of NO in the heart ([@b0105]). It should be noted that the anti-proliferative effect of NO and therefore of [l]{.smallcaps}-arginine, was observed during [l]{.smallcaps}-arginine treatment of existing pathological myocardial hypertrophy, a condition that is known to be associated with reduced NO biosynthesis ([@b0180]). Our previous studies demonstrated [l]{.smallcaps}-arginine-stimulated thermogenic activation in brown adipose tissue and acceleration of cold-induced antioxidative defense in the skeletal muscle of these animals ([@b0210], [@b0205]), suggesting that the observed cardiomyocyte hypertrophy in [l]{.smallcaps}-arginine-treated animals is an indirect consequence of increased peripheral circulatory demands. It remains to be elucidated whether [l]{.smallcaps}-arginine-induced hypertrophy of cardiomyocytes also includes direct NO-dependent or NO-independent mechanisms.

The most prominent effect of the NOS inhibitor, [l]{.smallcaps}-NAME, on rat myocardia observed in this study was fibrosis which was demonstrated as an increase in interstitial connective tissue volume density accompanied by increased collagen abundance in the interstitium. This effect was followed by cardiomyocyte hypertrophy despite a decrease in their volume density. These alterations were observed in both the room temperature- and the cold-acclimated [l]{.smallcaps}-NAME-treated groups, compared with the appropriate controls. When compared to the room temperature-acclimated group treated with [l]{.smallcaps}-NAME, identical treatment in cold-acclimated animals additionally enhanced interstitial fibrosis.

Pathological cardiac hypertrophy is characterized not only by the growth of myocardial fibers, but also by changes in cardiac architecture and cellular metabolism and, finally, by myocardial dysfunction with an increased morbidity and mortality. Specific genetic expression profiles, different from the adaptive profiles involved in physiological hypertrophy, are activated ([@b0155]). Pressure or volume overload causes initial hypertrophy, which represents a compensatory mechanism for maintaining cardiac function. If these stimuli persist, structural and functional cardiac anomalies develop. Thus, cardiac sarcomeres become bigger with abnormal proteins, resulting in a bioenergetics deficit that affects their function. The cardiac muscle fibers are disorganized, and separated by an excessive interstitial connective tissue since collagen metabolism is changed, resulting in a decreased degradation and an increased deposition of collagen in the extracellular matrix ([@b0060], [@b0230]). In these initial phases, collagen composition is normal with an enlarged ventricle ([@b0055]). However, with long-term myocardial remodeling, there is a buildup of fibroblasts and extracellular matrix proteins, causing abnormal structure and function in the heart, resulting in the condition known as myocardial fibrosis ([@b0025], [@b0110]) which is closely related to the amount of ventricular hypertrophy ([@b0055]). Consequently, myocardial fibrosis causes regional myocardial dysfunction ([@b0220]).

The mechanisms responsible for myocardial fibrosis in hypertrophy are not fully understood. However, growth factors such as FGF-2, TGFβ, and platelet-derived growth factor, and plasma hormones such as AngII, endothelin-1 and catecholamine, have been found to contribute to the regulation of this process ([@b0055]). With regard to the effects of chronic [l]{.smallcaps}-NAME administration, inhibited NOS activity in the myocardium, brain and kidney, and induced hypertension, hypertrophy and fibrotic remodeling of the left ventricle have been demonstrated, suggesting that chronic [l]{.smallcaps}-NAME treatment could be used in a model of pathological cardiac hypertrophy ([@b0255]). Moreover, in various conditions (the absence of coenzyme tetrahydrobiopterin, BH4; [l]{.smallcaps}-arginine deficiency; enhanced levels of free radicals, and the presence of different NOS inhibitors, [l]{.smallcaps}-NAME) NOS reduces molecular oxygen rather than [l]{.smallcaps}-arginine, resulting in the production of superoxide rather than NO, a phenomenon known as "NOS uncoupling" ([@b0175]). In a positive feedback manner, the activation of superoxide source (uncoupled eNOS) may provoke the formation of superoxide and/or ONOO--, which, in turn, oxidizes BH4 to BH3 radical, and leads to further ROS/RNS formation ([@b0120]). Consequently, scavenging of endogenous NO by superoxide anions may contribute to the diminished role of NO in the regulation of cardiac hypertrophy.

Myocardial structural alterations such are fibrosis and an increase in collagenous proteins were described after 4 weeks of [l]{.smallcaps}-NAME administration ([@b0185], [@b0180]), while extensive areas of fibrosis and myocardial necrosis were observed after 8 weeks of [l]{.smallcaps}-NAME administration ([@b0170]). It should be mentioned that the dose of [l]{.smallcaps}-NAME used in our study (approximately 10 mg/kg/day) was four times lower than that in the above-mentioned experiments (40 mg/kg/day), and is considered a low dose which was demonstrated to have no toxic effects ([@b0240]).

In conclusion, chronic [l]{.smallcaps}-arginine supplementation induces a low level right ventricular hypertrophy in room temperature-acclimated rats and significantly augments ventricular hypertrophy in cold-acclimated animals. This [l]{.smallcaps}-arginine-induced ventricular hypertrophy could be considered physiological, since no signs of myocardial fibrosis were observed. In contrast, chronic treatment with [l]{.smallcaps}-NAME, an inhibitor of NOSs, caused pathological right ventricular hypertrophy with signs of myocardial fibrosis, demonstrating the importance of NO depletion in the development of cardiovascular disease.
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